Get the Stockscreener App
7.49
1.19%
-0.09
Pre-market:
7.56
0.07
+0.93%
Arvinas Inc stock is traded at $7.49, with a volume of 575.60K.
It is down -1.19% in the last 24 hours and down -17.51% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$7.58
Open:
$7.66
24h Volume:
575.60K
Relative Volume:
0.66
Market Cap:
$483.26M
Revenue:
$89.40M
Net Income/Loss:
$-221.30M
P/E Ratio:
-2.3001
EPS:
-3.2564
Net Cash Flow:
$-256.90M
1W Performance:
+4.76%
1M Performance:
-17.51%
6M Performance:
-39.30%
1Y Performance:
+1.35%
1-Day Range:
$7.38
$7.826
1-Week Range:
$6.97
$7.826
52-Week Range:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.49 | 483.26M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Price-Driven Insight from (ARVN) for Rule-Based Strategy - Stock Traders Daily
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas sharpens pipeline focus after first PROTAC approval, eyes key trial data - MSN
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - MarketBeat
Arvinas joins MJFF initiatives to advance LRRK2 research - BioWorld News
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease - marketscreener.com
Arvinas, Inc. Joins The Michael J. Fox Foundation's LITE And PPMI Programs To Advance New Therapies Targeting LRRK2 For Parkinson's Disease - marketscreener.com
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI - GlobeNewswire
Arvinas joins Michael J. Fox effort to develop new Parkinson's therapies - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ARVN Reiterates by Stephens & Co. -- Price Target Maintained at $18 - GuruFocus
ARVN: First PROTAC degrader approved; pipeline prioritization and key milestones drive focus - TradingView
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development - TipRanks
ArvinasAnnounces Re-Prioritization Of Portfolio Following Strategic ReviewSEC Filing - TradingView
Arvinas reprioritizes pipeline, to complete ARV-806 Phase 1 data and seek out-license; cash runway into H2 2028 - TradingView
Arvinas (ARVN) refocuses ARV-806 strategy and projects cash runway into second half of 2028 - Stock Titan
(ARVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Full Transcript: Arvinas Q1 2026 Earnings Call - Benzinga
Monaco Asset Management SAM Has $833,000 Holdings in Arvinas, Inc. $ARVN - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - The Manila Times
Arvinas, Inc. to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 3, 2026 - Quiver Quantitative
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Arvinas Inc. (ARVN) Stabilizes Near Support Amid Biotech Sector CautionVolatility Skew - thelegaladvocate.com
Arvinas Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - 富途牛牛
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):